NYSE: HIMSHims & Hers Health Inc Stock
$55.48-1.67 (-2.92%)
Updated Jun 13, 2025
HIMS Price
$55.48
Fair Value Price
N/A
Market Cap
$12.42B
52 Week Low
$13.47
52 Week High
$72.98
P/E
74.97x
P/B
22.61x
P/S
3.68x
PEG
3.01x
Dividend Yield
N/A
Revenue
$1.78B
Earnings
$164.40M
Gross Margin
77%
Operating Margin
6.71%
Profit Margin
9.2%
Debt to Equity
0.62
Operating Cash Flow
$334M
Beta
1.62
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
HIMS Overview
Hims, Inc. manufactures men's wellness products. It offers products, including hair loss prevention medicines, sexual wellness products, skincare products, and oral care products. The company also provides sweaters, jackets, corduroy, sport coats, wool overcoat, leather boots, flannel, shirts, caps, and candles. It sells its products online. The company was incorporated in 2013 and is based in San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine HIMS's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Household & Personal Product
Industry Rating
C
HIMS
Ranked#3 of 26
Ranked#3 of 26
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $7.56 | A | |
| $5.74 | B | |
| $9.15 | B |
Be the first to know about important HIMS news, forecast changes, insider trades & much more!
HIMS News
Overview
Due Diligence Score
–
Industry Average (32)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HIMS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HIMS ($55.48) is trading above its intrinsic value of $10.56, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HIMS is poor value based on its earnings relative to its share price (74.97x), compared to the US market average (31.36x)
P/E vs Market Valuation
HIMS is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more HIMS due diligence checks available for Premium users.
Valuation
HIMS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
74.97x
Industry
25.33x
Market
31.36x
HIMS is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
HIMS is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
HIMS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
22.61x
Industry
7.23x
HIMS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HIMS price to earnings growth (PEG)
For valuing profitable companies with growth potential
HIMS is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
HIMS's financial health
Profit margin
Revenue
$586.0M
Net Income
$49.5M
Profit Margin
8.4%
HIMS's Earnings (EBIT) of $119.80M... subscribe to Premium to read more.
Interest Coverage Financials
HIMS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$891.7M
Liabilities
$342.5M
Debt to equity
0.62
HIMS's short-term assets ($446.96M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HIMS's short-term assets ($446.96M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HIMS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
HIMS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$109.1M
Investing
-$32.8M
Financing
-$23.0M
HIMS's operating cash flow ($334.34M)... subscribe to Premium to read more.
Debt Coverage Financials
HIMS vs Household & Personal Product Stocks
Hims & Hers Health Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.